Obsidian: Fine-tuning therapeutic protein expression with approved drugs

How Obsidian is designing small molecule-controlled proteins for use in cell therapies and beyond

Obsidian is building a tool kit of engineered proteins whose expression can be finely tuned with FDA-approved small molecules, and its first application is in boosting the efficacy of cell therapies through a deal with Celgene. Founded by Atlas Venture in 2015, the start-up thinks it can deploy the tech in any modality where proteins can be manufactured.

The centerpieces of Obsidian Therapeutics Inc.’s technology are its drug-responsive domains -- small domains that are fused to a protein of interest. Each domain

Read the full 815 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE